Citadel Advisors’s Intellipharmaceuticals International Inc. IPCI Stock Holding History

Citadel Advisors’s Portfolio IPCI Stock Details IPCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,126	Closed	-$8.14K	–	9100
2017 Q4	$9K	Sell	1,126 -959	-46%	-$8.71K	﹤0.01%	7898
2017 Q3	$21K	Buy	+2,085	New	+$29.7K	﹤0.01%	7354
2017 Q1	–	Sell	-1,743	Closed	-$44.9K	–	8352
2016 Q4	$50K	Buy	+1,743	New	+$48.7K	﹤0.01%	6871
2016 Q3	–	Sell	-1,449	Closed	-$22K	–	8076
2016 Q2	$22K	Buy	+1,449	New	+$26.4K	﹤0.01%	6581

Other funds holding IPCI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

FANJ

Financial Architects (New Jersey) Marlton, New Jersey $663M AUM 15.53% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors's IPCI Position: Q1 2018 in Review

Citadel Advisors sold out of Intellipharmaceuticals International Inc. (IPCI) in Q1 2018, closing a stake of 1,126 shares — an estimated $8.14K sold.

Citadel Advisors first reported a position in IPCI in Q2 2016 and held it in 4 quarters. The position peaked at $50K in Q4 2016. 24 funds tracked by Wall St. Rank hold IPCI as of Q1 2018.

Citadel Advisors reported no remaining Intellipharmaceuticals International Inc. position as of Q1 2018 after selling out during the quarter.
Citadel Advisors sold 1,126 Intellipharmaceuticals International Inc. shares in Q1 2018, an estimated $8.14K.
Citadel Advisors first reported a position in Intellipharmaceuticals International Inc. in Q2 2016 and held it in 4 quarters.
Citadel Advisors's Intellipharmaceuticals International Inc. position peaked at $50K in Q4 2016.
24 funds tracked by Wall St. Rank held Intellipharmaceuticals International Inc. as of Q1 2018.

Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.